IMCR insider trading
NasdaqGS HealthcareImmunocore Holdings plc — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About Immunocore Holdings plc
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 3 clinical trial to treat advanced cutaneous melanoma and adjuvant uveal melanoma; and brenetafusp that is in Phase 3 clinical trial to treat first-line advanced cutaneous melanoma and in a Phase 1/2 clinical trial in multiple tumor types. In addition, the company's products under development include IMC-R117C (PIWIL-1) that is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, including colorectal cancer; IMC-P115C (PRAME-HLE-A02) that is in Phase 1 clinical trial for patients with tumors that express PRAME; IMC-M113V that is in Phase 1 clinical trials for a potential functional cure in human immunodeficiency virus (HIV); and IMC-I109V that is in Phase 1 clinical trials for a potential functional cure in hepatitis B virus (HBV). Further, it develops IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-S118AI to treat type 1 diabetes; and IMC-U120AI to treat atopic dermatitis. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Company website: www.immunocore.com
IMCR insider activity at a glance
FilingIQ has scored 71 insider transactions for IMCR since Jan 3, 2024. The most recent filing in our index is dated Feb 18, 2026.
Across the full history, 4 open-market purchases
and 30 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on IMCR insider trades is 63.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest IMCR Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading IMCR
13F funds holding IMCR
Frequently asked
- How many insider trades does FilingIQ track for IMCR?
- FilingIQ tracks 71 Form 4 insider transactions for IMCR (Immunocore Holdings plc), covering filings from Jan 3, 2024 onwards. 18 of those were filed in the last 90 days.
- Are IMCR insiders net buyers or net sellers?
- Across the full Form 4 history for IMCR, 4 transactions (6%) were open-market purchases and 30 (42%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does IMCR insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is IMCR in?
- Immunocore Holdings plc (IMCR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.67B.
Methodology & sources
Every IMCR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.